Autopsy report · NCT01367301

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

“Lack of accrual. PI left the institution”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 7 years 1 month before it stopped.
• 14 participants enrolled.
• Results were posted on the registry 5 years after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Albert Einstein College of Medicine

Sponsor type

University, hospital or other

Conditions

Stage IA Uterine Sarcoma; Stage IB Uterine Sarcoma; Stage IC Uterine Sarcoma; Stage IIA Uterine Sarcoma; Stage IIB Uterine Sarcoma; Stage IIIA Uterine Sarcoma

Interventions

paclitaxel; carboplatin; external beam radiation therapy; brachytherapy; intensity-modulated radiation therapy; laboratory biomarker analysis

Participants

14

Sites

1

Countries

United States

Trials that died the same way

• Transverse Abdominus Plane Block Study
  “No Accrual. PI left Institution” (88% match in meaning)
• PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
  “Due to PI leaving the institution” (87% match in meaning)
• Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure (The SPARK Trial)
  “PI left the institution” (84% match in meaning)
• Pre-op Femoral Nerve Block for Hip Fracture
  “PI no longer at institution” (81% match in meaning)
• Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
  “PI leaving institution” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.